{"schema_version":"secwatch.filing_event.v1","accession":"0000920148-23-000023","form_type":"8-K","ticker":"LH","cik":"0000920148","company_name":"LABCORP HOLDINGS INC.","filed_at":"2023-04-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:42.809015+00:00","generated_at":"2026-06-16T18:05:12.003037+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Labcorp Q1 revenue down 3.1% to $3.78B; adj EPS $3.82 vs $6.11; guides FY adj EPS $16.25-$17.75","bullets":["Q1 revenue $3.78B vs $3.90B prior year; Base Business organic growth +7.9% offset by COVID-19 Testing decline -11.6%.","Diluted EPS $2.39, adjusted EPS $3.82; prior year $5.23 and $6.11 respectively; free cash flow $27M vs $239M.","FY2023 guidance: adjusted EPS narrowed to $16.25-$17.75 (midpoint unchanged), free cash flow $1.0B-$1.2B.","Diagnostics adj op income $441.5M (18.5% margin) down from $683.1M (27.8%); Drug Development adj op income $123.9M (8.8%) down from $168.6M (11.6%).","Spin of Clinical Development (Fortrea) on track for mid-2023; quarterly dividend $0.72/share payable June 8, 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0000920148-23-000023","json":"https://secwatch.observer/filing/0000920148-23-000023.json","markdown":"https://secwatch.observer/filing/0000920148-23-000023.md","text":"https://secwatch.observer/filing/0000920148-23-000023.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/920148/000092014823000023/0000920148-23-000023-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/920148/000092014823000023/lh-20230425.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-16T18:05:12.003037+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b51c78ac7c1322c5136757e19f6b294a7387abe9","claim":"LABCORP HOLDINGS INC. updated its full-year 2023 guidance (reaffirmed).","evidence_excerpt":"• Full-Year 2023 Guidance: Adjusted EPS narrowed to $16.25 to $17.75 with midpoint unchanged and Free Cash Flow remains at $1.0 billion to $1.2 billion","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/920148/000092014823000023/0000920148-23-000023-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"full-year 2023"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}